A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder: A high placebo response

Teri Pearlstein; E. Spurell; L. A. Hohlstein; V. Gurney; J. Read; C. Fuchs; M. B. Keller

doi:10.1007/s00737-003-0172-8

A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder: A high placebo response

Teri Pearlstein^*, E. Spurell, L. A. Hohlstein, V. Gurney, J. Read, C. Fuchs, M. B. Keller

^*Corresponding author for this work

School of Mathematical Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

Twenty subjects with binge eating disorder were randomly assigned to flexible-dose fluvoxamine or placebo for 12 weeks. A significant reduction in binge frequency, Beck Depression Inventory scores and the eating concern, shape concern and weight concern subscales of the Eating Disorder Examination were noted for both fluvoxamine (n = 9) and placebo (n = 11) groups. There were no significant differences between fluvoxamine and placebo for any treatment outcome variables. The findings from this small trial contribute to the inconsistent results of antidepressant studies in binge eating disorder.

Original language	English
Pages (from-to)	147-151
Number of pages	5
Journal	Archives of Women's Mental Health
Volume	6
Issue number	2
DOIs	https://doi.org/10.1007/s00737-003-0172-8
State	Published - Apr 2003

Keywords

Binge eating disorder
Fluvoxamine
Placebo

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00737-003-0172-8

Cite this

@article{8deb3dc4cea34909bf7e08cedff61e07,

title = "A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder: A high placebo response",

abstract = "Twenty subjects with binge eating disorder were randomly assigned to flexible-dose fluvoxamine or placebo for 12 weeks. A significant reduction in binge frequency, Beck Depression Inventory scores and the eating concern, shape concern and weight concern subscales of the Eating Disorder Examination were noted for both fluvoxamine (n = 9) and placebo (n = 11) groups. There were no significant differences between fluvoxamine and placebo for any treatment outcome variables. The findings from this small trial contribute to the inconsistent results of antidepressant studies in binge eating disorder.",

keywords = "Binge eating disorder, Fluvoxamine, Placebo",

author = "Teri Pearlstein and E. Spurell and Hohlstein, {L. A.} and V. Gurney and J. Read and C. Fuchs and Keller, {M. B.}",

year = "2003",

month = apr,

doi = "10.1007/s00737-003-0172-8",

language = "אנגלית",

volume = "6",

pages = "147--151",

journal = "Archives of Women's Mental Health",

issn = "1434-1816",

publisher = "Springer-Verlag Wien",

number = "2",

}

TY - JOUR

T1 - A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder

T2 - A high placebo response

AU - Pearlstein, Teri

AU - Spurell, E.

AU - Hohlstein, L. A.

AU - Gurney, V.

AU - Read, J.

AU - Fuchs, C.

AU - Keller, M. B.

PY - 2003/4

Y1 - 2003/4

N2 - Twenty subjects with binge eating disorder were randomly assigned to flexible-dose fluvoxamine or placebo for 12 weeks. A significant reduction in binge frequency, Beck Depression Inventory scores and the eating concern, shape concern and weight concern subscales of the Eating Disorder Examination were noted for both fluvoxamine (n = 9) and placebo (n = 11) groups. There were no significant differences between fluvoxamine and placebo for any treatment outcome variables. The findings from this small trial contribute to the inconsistent results of antidepressant studies in binge eating disorder.

AB - Twenty subjects with binge eating disorder were randomly assigned to flexible-dose fluvoxamine or placebo for 12 weeks. A significant reduction in binge frequency, Beck Depression Inventory scores and the eating concern, shape concern and weight concern subscales of the Eating Disorder Examination were noted for both fluvoxamine (n = 9) and placebo (n = 11) groups. There were no significant differences between fluvoxamine and placebo for any treatment outcome variables. The findings from this small trial contribute to the inconsistent results of antidepressant studies in binge eating disorder.

KW - Binge eating disorder

KW - Fluvoxamine

KW - Placebo

UR - http://www.scopus.com/inward/record.url?scp=0037692950&partnerID=8YFLogxK

U2 - 10.1007/s00737-003-0172-8

DO - 10.1007/s00737-003-0172-8

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 12720065

AN - SCOPUS:0037692950

SN - 1434-1816

VL - 6

SP - 147

EP - 151

JO - Archives of Women's Mental Health

JF - Archives of Women's Mental Health

IS - 2

ER -

A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder: A high placebo response

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this